Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first ...
Get free access to Word, Excel, and PowerPoint using Microsoft 365 for the web (formerly Office).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback